Abstract YO38
Case summary
Thymomas constitute 10% of mediastinal tumours and are often benign epithelial neoplasms of the thymus gland. Up to a third of cases of thymomas are malignant and causes local infiltration to surrounding structures. Rarely, they metastasize to distant organs. We report a case of slow growing thymoma which progressed into cerebral metastases. A 53 year old lady presented with 5 years history of a mediastinal tumour. She initially refused any therapy at the first presentation. She returned with an enlarging anterior mediastinal mass causing chest pain and cough. Thoracic CT revealed a 10 cm right anterior mediastinal mass abutting the pericardium. Histopathological examination of the mediastinal mass biopsy indicated thymoma. She was planned for surgical resection however developed acute neurological symptoms of headache, confusion and memory loss. Cranial MRI showed multiple lesions in the temporoparietal lobe, left frontal lobe, internal capsule and basal ganglia. Stereotactic biopsy confirmed metastases from a B1 type thymoma. She deteriorated rapidly and died without any possible intervention. Intracranial metastases from thymic tumours are rare. To date, there are 45 cases reported within the literature of cerebral metastases from thymic epithelial tumours. The median survival with multiple cerebral metastases is merely 64 days, hence high suspicion of distant spread in thymic epithelial tumours and prompt surgery may potential improve the outcome in this group of patients.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract